Remoxipride
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Non-proprietary name | Remoxipride | |||||||||||||||
other names |
( S ) -3-bromo- N - (1-ethyl-2-pyrrolidinylmethyl) -2,6-dimethoxybenzamide ( IUPAC ) |
|||||||||||||||
Molecular formula |
|
|||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
ATC code | ||||||||||||||||
Drug class | ||||||||||||||||
properties | ||||||||||||||||
Molar mass |
|
|||||||||||||||
Physical state |
firmly |
|||||||||||||||
Melting point |
173 ° C |
|||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Remoxiprid is an atypical neuroleptic that was used in psychiatry in the early 1990s . From the chemical structure it is a benzamide .
history
Remoxiprid was approved for the treatment of schizophrenic psychoses from 1991 to the end of 1993 . The trade name of the original preparation was Roxiam ; the daily dose was 150–450 mg (max. 600 mg) in the form of oral capsules, and a solution for injection was also available.
Withdrawal from the market
At the end of 1993, ROXIAM was taken off the market worldwide by the manufacturer when the regulatory approval for Remoxiprid threatened to be revoked. The cause was fatal cases of aplastic anemia , damage to blood formation in the bone marrow caused by remoxipride ( risk 1 in 2000). The risk-benefit ratio of this low-potency neuroleptic was therefore clearly negative.
Individual evidence
- ^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, p. 1401, ISBN 978-0-911910-00-1 .
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.